updated 4/19/2011 7:16:46 AM ET 2011-04-19T11:16:46

DALLAS, April 19, 2011 (GLOBE NEWSWIRE) -- MicroStockProfit.com announces an investment report featuring Chelsea Therapeutics International Ltd. (Nasdaq:CHTP). The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

The full report is available at: www.microstockprofit.com/lp/CHTP

Chelsea Therapeutics (CHTP) is a development stage pharmaceutical company that focuses on acquiring, developing and commercializing products for the treatment of a variety of human diseases. Its most advanced drug candidate, Northera (droxidopa), is an orally active synthetic precursor of norepinephrine initially being developed for the treatment of neurogenic orthostatic hypotension. In addition to Droxidopa, the Company is also developing a portfolio of metabolically inert oral antifolate molecules engineered to have potent anti-inflammatory and anti-tumor activity to treat a range of immunological disorders, including two clinical stage product candidates CH-1504 and CH-4051. Preclinical and clinical data suggest superior safety and tolerability, as well as increased potency versus methotrexate (MTX), currently the leading antifolate treatment and standard of care for a broad range of abnormal cell proliferation diseases.

This newsletter has been helping traders make great investment decisions on CHTP; click here for a 25% discount offer.

In the report, the analyst notes:

"Shares of CHTP soared Monday after the biotechnology company announced it would file a new drug application (NDA) for its hypotension treatment in the third quarter."

"The Company plans to file its NDA for Northera for the treatment of symptomatic NOH based on combined efficacy data from its two completed Phase III studies in NOH, Study 301 and Study 302, during the third quarter of 2011. Late in December, CHTP was told by the FDA that it does not need further efficacy studies for the drug and could file for approval based on the combined data from its 301 and 302 studies."

To read the entire report visit: www.microstockprofit.com/lp/CHTP

See what investors are saying about CHTP at http://www.stockhideout.com

Get breaking news on CHTP at http://thestockmarketwatch.com/

MicroStockProfit.com is a small-cap research and investment commentary provider. MicroStockProfit.com strives to provide a balanced view of many promising small-cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the public information available on them. For more information on MicroStockProfit please visit: http://www.microstockprofit.com

MicroStockProfit.com Disclosure

MicroStockProfit.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. MicroStockProfit.com is a Web site wholly owned by BlueWave Advisors, LLC. Neither MicroStockProfit.com nor its affiliates have a beneficial interest in the mentioned company; nor have they received compensation of any kind for any of the companies listed in this communication. Please read our report and visit our Web site, MicroStockProfit.com, for complete risks and disclosures.

CONTACT: Brian Johnson
         info@microstockprofit.com
         1-888-307-2850

© Copyright 2012, GlobeNewswire, Inc. All Rights Reserved

Discuss:

Discussion comments

,

Most active discussions

  1. votes comments
  2. votes comments
  3. votes comments
  4. votes comments

Data: Latest rates in the US

Home equity rates View rates in your area
Home equity type Today +/- Chart
$30K HELOC FICO 4.97%
$30K home equity loan FICO 5.23%
$75K home equity loan FICO 4.66%
Credit card rates View more rates
Card type Today +/- Last Week
Low Interest Cards 13.28%
13.21%
Cash Back Cards 17.73%
17.70%
Rewards Cards 17.00%
16.96%
Source: Bankrate.com